DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
McDermott DF, Sosman JA, Sznol M. et al.
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.
J Clin Oncol 2016;
34: 833-842
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.